Edition:
India

Zoetis Inc (ZTS.N)

ZTS.N on New York Stock Exchange

52.17USD
8:37pm IST
Change (% chg)

$0.49 (+0.95%)
Prev Close
$51.68
Open
$51.86
Day's High
$52.48
Day's Low
$51.68
Volume
130,954
Avg. Vol
1,005,622
52-wk High
$53.13
52-wk Low
$38.26

ZTS.N

Chart for ZTS.N

About

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively,... (more)

Overall

Beta: 1.07
Market Cap(Mil.): $25,521.27
Shares Outstanding(Mil.): 493.83
Dividend: 0.10
Yield (%): 0.81

Financials

  ZTS.N Industry Sector
P/E (TTM): 37.41 29.74 30.35
EPS (TTM): 1.38 -- --
ROI: 11.74 15.90 15.27
ROE: 48.97 17.00 16.60

BRIEF-Zoetis sees Q3 adjusted EPS $0.52

* Zoetis inc- increases diluted eps to $1.66 - $1.75 on a reported basis, or $1.91 - $1.96 on an adjusted basis for full year 2016

02 Nov 2016

UPDATE 1-MOVES-Pershing Square's Valeant analyst to exit, Ackman sees stock rising

BOSTON, Aug 26 Billionaire investor William Ackman said on Friday that Jordan Rubin, who had worked closely on Pershing Square Capital Management's controversial investment in battered drug maker Valeant Pharmaceuticals, is leaving the hedge fund.

27 Aug 2016

Animal spirits: consumers' devotion lifts pet-care stocks

NEW YORK, Aug 24 Americans' attachment to their pets has fostered a $60 billion industry that is producing best-in-breed stock performance.

25 Aug 2016

UPDATE 1-Valeant hires Zoetis's Paul Herendeen as CFO

Aug 22 Valeant Pharmaceuticals International Inc named Zoetis Inc executive Paul Herendeen as its chief financial officer, replacing Robert Rosiello, the latest in a series of management changes at the Canadian drugmaker.

22 Aug 2016

Valeant names former Zoetis executive Paul Herendeen as CFO

Aug 22 Valeant Pharmaceuticals International Inc said on Monday former Zoetis Inc executive Paul Herendeen will take over as chief financial officer from Robert Rosiello, effective immediately.

22 Aug 2016

BRIEF-Zoetis appoints Glenn David as CFO

* Zoetis announces appointment of Glenn David as executive vice president and chief financial officer

22 Aug 2016

BRIEF-Pershing Square Capital Management cuts share stake in Zoetis by 49 pct

* Pershing Square Capital Management cuts share stake in Zoetis by 49 percent to 21.1 million shares - SEC filing Source text for quarter ended June 30, 2016: http://bit.ly/2btCh7t Source text for quarter ended March 31, 2016: http://bit.ly/2b9rcZp

16 Aug 2016

BRIEF-Zoetis acquires Scandinavian Micro Biodevices to extend pipeline in veterinary diagnostics

* Zoetis acquires scandinavian micro biodevices to extend its pipeline in diagnostics for veterinary use

08 Aug 2016

BRIEF-Schouw & Co: Incuba Invest divests shares in Scandinavian Micro Biodevices

* Incuba Invest, an associate, in which Schouw & Co holds a 49 pct stake, has entered into a share purchase agreement regarding its shares in Scandinavian Micro Biodevices APS

08 Aug 2016

BRIEF-Zoetis reports Q2 earnings per share $0.45

* Q2 earnings per share view $0.44 -- Thomson Reuters I/B/E/S

03 Aug 2016

Competitors

  Price Chg
Merck & Co., Inc. (MRK.N) $60.85 +0.73
Bayer AG (BAYGn.DE) €94.11 +0.94
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.68 +1.60
Eli Lilly and Co (LLY.N) $67.70 +0.51

Earnings vs. Estimates